secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-127054
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma reports $26.9M cash, no debt; continues strategic alternatives review
--------------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments at Sept 30, 2024: $26.9M; no outstanding debt.
- Strategic alternatives review ongoing; Oppenheimer & Co. acting as exclusive financial advisor.
- Reduction-in-force initiated as part of cash preservation efforts; further stages planned.
- No assurance that any transaction will result; updates only if Board determines disclosure appropriate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024127054/0000950170-24-127054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000095017024127054/meip-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-127054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer